IL6 and colitis: Furthermore, Li et al. (2017) demonstrated that BRB suppressed colitis-induced colorectal cancer progression in an in vivo DSS colitis murine model with Apc gene mutations, downregulating IL-6 and TNF-α and silencing the EGFR/ERK pathway [51].